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Abstract
Background: Despite high waiting list mortality rates, concern still exists on the appropriateness of using livers donated after circula-
tory death (DCD). We compared mortality and graft loss in recipients of livers donated after circulatory or brainstem death (DBD)
across two successive time periods.
Methods: Observational multinational data from the United Kingdom and Ireland were partitioned into two time periods (2008–2011
and 2012–2016). Cox regression methods were used to estimate hazard ratios (HRs) comparing the impact of periods on post-
transplant mortality and graft failure.
Results: A total of 1176 DCD recipients and 3749 DBD recipients were included. Three-year patient mortality rates decreased mark-
edly from 19.6 per cent in time period 1 to 10.4 per cent in time period 2 (adjusted HR 0.43, 95 per cent c.i. 0.30 to 0.62; P< 0.001) for
DCD recipients but only decreased from 12.8 to 11.3 per cent (adjusted HR 0.96, 95 per cent c.i. 0.78 to 1.19; P¼ 0.732) in DBD recipients
(P for interaction¼ 0.001). No time period-specific improvements in 3-year graft failure were observed for DCD (adjusted HR 0.80, 95%
c.i. 0.61 to 1.05; P¼ 0.116) or DBD recipients (adjusted HR 0.95, 95% c.i. 0.79 to 1.14; P¼ 0.607). A slight increase in retransplantation
rates occurred between time period 1 and 2 in those who received a DCD liver (from 7.3 to 11.8 per cent; P¼ 0.042), but there was no
change in those receiving a DBD liver (from 4.9 to 4.5 per cent; P¼ 0.365). In time period 2, no difference in mortality rates between
those receiving a DCD liver and those receiving a DBD liver was observed (adjusted HR 0.78, 95% c.i. 0.56 to 1.09; P¼ 0.142).
Conclusion: Mortality rates more than halved in recipients of a DCD liver over a decade and eventually compared similarly to mortal-
ity rates in recipients of a DBD liver. Regions with high waiting list mortality may mitigate this by use of DCD livers.
Introduction
Increased numbers of patients who require liver transplantation have
contributed to a chronic shortage of donors in many high-income
countries1–4. As a consequence, livers donated following circulatory
death (DCD) have been used increasingly to address the discrepancy
between the number of patients waiting to receive a liver transplant
and the number of suitable donor organs available2,4. Early analyses
that compared DCD livers with livers donated following brainstem
death (DBD) described inferior post-transplantation outcomes, espe-
cially in the early post-transplantation period2,5–8. Variable periods of
warm ischaemia during the procurement of DCD livers were found to
cause irreversible cellular damage and higher rates of postoperative
biliary complications, primary non-function (PNF), and hepatic artery
thrombosis (HAT)2,5–8.
These early single-centre reports of poorer graft and patient
survival contributed to differences internationally in how DCD
donors were utilized9. In some countries, there was reluctance to
maximize their use due to the risk of postoperative complications
and graft failure, whereas in other countries—including the
United Kingdom (UK) and Ireland—there was reliance on DCD
donors to provide liver transplantation to patients, and especially
hepatocellular carcinoma (HCC) patients, before their disease
progressed beyond the transplantable criteria4,10.
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Optimal utilization of grafts from DCD donors is most likely to
have been associated with a learning curve9. More recent publica-
tions from countries outside the UK describe improvements in
the use of DCD livers, including improved patient and graft sur-
vival and lower rates of biliary complications, PNF, and HAT11–15.
A recent analysis of the UK liver transplant waiting list indicated
that patients fair better by accepting an offer of a DCD liver
rather than waiting for a future offer of a better-quality donor
liver16.
Given that, proportionally, the UK continues to be the primary
proponent in the utilization of DCD livers, it is important to iden-
tify whether temporal improvements in patient and graft survival
have been observed. Also, with high rates of graft failure reported
previously9, and retransplantation as the only lifesaving option
in this event, it is important to investigate whether the rate of
retransplantation has changed over time. Using national data of
transplants carried out in the UK and Ireland, we investigated
whether there have been changes over time in short- and longer-
term post-transplant mortality for patients who received a DCD
or DBD liver. In order to understand changes in patient survival,
we also investigated changes over time in the rate of graft failure
and retransplantation and in the incidence of postoperative com-
plications. Finally, we provide an up-to-date comparison of post-
transplant mortality in patients receiving DCD and that in
patients who had DBD livers.
Patients and methods
Standard National Liver Transplant Registry
The Standard National Liver Transplant Registry contains de-
tailed information about all liver transplants carried out in all
seven liver transplant centres in the UK and Ireland17. It is man-
aged by NHS Blood and Transplant17. This registry was used to
identify recipients of a controlled DCD or DBD liver transplant
and to capture information on donor and recipient characteris-
tics, including post-transplantation outcomes (HAT, biliary tract
leak, and biliary tract stricture) recorded at 3 months and the
date and cause of death and graft failure17.
Study population
All patients aged 18 years or older who had received a first-time
elective liver transplant between 1 January 2008 and 31
December 2016 were eligible for inclusion (Fig. S1). Recipients
were dichotomized into two groups: those transplanted using a
DCD liver; and those transplanted using a DBD liver. To limit het-
erogeneity of the study cohort, patients who underwent trans-
plantation for types of liver cancer other than HCC and those
who underwent multivisceral, superurgent, domino, or living-
related liver transplantations were excluded, as well as those
who received a liver transplant for acute liver failure (including
auxiliary transplantation). We also excluded patients whose sur-
vival data were missing. This study complies with the STROBE
statement for retrospective studies18.
Inclusion period and two time periods
Patients were grouped into those who had received a transplant
between 1 January 2008 and 31 December 2011 (time period 1)
and those between 1 January 2012 and 31 December 2016 (time
period 2). The start of time period 1 coincides with the introduc-
tion of donor allocation policies that are based on predicted wait-
ing list mortality19. We chose the start of time period 2 based on
pragmatic considerations, creating as much as possible two time
periods of equal duration while using calendar years.
Donor and recipient characteristics
Recipients’ functional status at the time of transplantation was
assessed using a 5-point scale, ranging from ‘able to carry out
normal activity without restriction’ to ‘completely reliant on
nursing/medical care’20. The United Kingdom Model for End-
Stage Liver Disease (UKELD) score, derived from the international
normalized ratio (INR), serum bilirubin, sodium, and creatinine,
was used to score recipients’ severity of liver disease19, and val-
ues for ethnicity were categorized into white and non-white
groups. Changes over time in overall donor quality was measured
using the UK Donor Liver Index (DLI), derived from donor age,
sex, height, type (DCD donor or not), serum bilirubin, smoking
history, and whether the liver was split, with larger values repre-
senting poorer donor livers21.
Cold ischaemic time (CIT) was defined as the duration be-
tween start of cold perfusion in the donor to start of blood flow
through the organ in the recipient22. Warm ischaemic time (WIT)
was separated into agonal and asystolic time periods23. Agonal
time was defined as the period between withdrawal of life-
sustaining treatment and circulatory arrest, and asystolic time
was defined from the time of circulatory death to the time the do-
nor liver was placed in cold storage23. A small proportion of donor
livers included in time period 2 of this analysis would have been
subjected to normothermic machine perfusion, but these
patients could not be specifically identified from the Standard
National Liver Transplant Registry.
Donor and recipient selection and organ
procurement
All DCD donors included in this analysis were procured under
controlled circumstances where potentially life-sustaining treat-
ment was withdrawn after further intervention was deemed fu-
tile (Maastricht III) or circulatory death occurred in a DBD donor
(Maastricht IV)2. Criteria for DCD donor selection and postwith-
drawal haemodynamic parameters varied among liver transplant
centres but broadly followed the experience detailed by Muiesan
et al.24 Administration of heparin or prior dissection of femoral
vessels is prohibited by UK law2. Death was declared at 5 minutes
following cardiac arrest and all UK liver procurement centres
used a super-rapid recovery technique, although the type of pres-
ervation fluid, bag pressure, and use of simultaneous perfusion
techniques varied2.
During the study period, DBD and DCD liver allocation in the
UK and Ireland was organized locally and centres selected recipi-
ents according to local criteria. In terms of DBD transplantation,
patients on local waiting lists were prioritized according to the
UKELD scoring system that was designed to predict waiting list
mortality19,25. In terms of DCD transplantation, local centres
could allocate DCD donors outside of the UKELD scoring system
if they felt there was a more suitable recipient further down the
list. The scoring systems did not award additional points to
patients on the waiting list with HCC19,25.
Statistical analysis
Percentages were used to describe categorical results and the chi-
square test was used to compare differences. Biliary complica-
tions were stratified into those that required treatment for a bili-
ary tract leak or a biliary tract stricture. Biliary complications
were reported as complications in their own right and also as a
cause of graft failure. To calculate causes of death and graft fail-
ure, the total number of patients in each cohort was used as the
denominator. Postoperative renal failure was defined as any
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patient requiring renal replacement therapy. Categorical varia-
bles were presented as proportions and continuous variables
were presented as means with standard deviations.
Kaplan–Meier methods were used to compare patient and
graft survival between successive time periods of transplanta-
tion. Follow-up was censored at 3 years after transplantation or
on the last follow-up visit before 7 April 2017, whichever occurred
earlier. Graft failure was defined as either retransplantation or
patient death. A 3-year follow-up was chosen to reflect the time
period in which most complications associated with DCD trans-
plantation would be expected to occur2,26.
Multivariable Cox regression models were used to estimate
hazard ratios (HRs) that represented the relative differences in
post-transplant mortality and graft loss. Models were fitted
with adjustment for donor and recipient characteristics, and a
categorical variable for transplant centre was also included in
each model27. Interaction terms were included in the models
to investigate whether the effect of time period differed
according to whether a DCD or DBD liver had been used if the
recipient had been transplanted for HCC or non-HCC indica-
tions. The significance of the interaction term was tested us-
ing a global Wald test. The outputs of our prediction models
are reported in accordance with the Transparent Reporting of
a multivariable prediction model for Individual Prognosis Or
Diagnosis (TRIPOD) statement28.
Retransplantation rates were calculated, with death consid-
ered as a competing risk. Fine and Gray regression was used to
estimate adjusted subdistribution HRs to investigate the differen-
ces in retransplantation rates between time periods 1 and 2, with
adjustment for donor and recipient characteristics29.
Three sensitivity analyses were performed. First, the post-
transplantation period was partitioned into two separate epochs
of follow-up time and the impact of time period on short- and
longer-term mortality and graft failure was assessed4,30. Second,
a separate Cox regression model was built to compare mortality
with adjustment for WIT, in addition to all other donor and recip-
ient characteristics. Third, another Cox model was built that ad-
ditionally adjusted for transplant centre volume. In this model,
transplant centre annual volumes of DCD and DBD transplants
were measured separately.
Missing donor and recipient characteristics were imputed us-
ing chained equations, creating ten complete data sets31,32. In the
imputation procedure, all of the donor and recipient variables
used in the case mix adjustment were used to predict missing
values, including the outcome variables33. The Cox regression
results for each of these data sets were pooled using Rubin’s
rules31. Stata V15 (StataCorp, College Station, Texas, USA) was
used for all statistical analyses. A P-value of < 0.050 was consid-
ered statistically significant.
Results
A total of 4925 adult recipients of first elective liver transplants
were included (Fig. S1). Of these recipients, 1176 (23.9 per cent) re-
ceived a DCD liver, and 3749 (76.1 per cent) a DBD liver. Use of
DCD livers increased markedly (Fig. 1).
Comparing donor characteristics, we found that recipients of
a DCD liver were more likely to have male donors and to have re-
ceived a liver with evidence of capsular damage sustained during
retrieval, but they were less likely to have received a liver with
signs of steatosis, and the average CIT was shorter than in recipi-
ents of a DBD liver (Table 1). Considering DCD recipients only,
there were no time period-related differences in WIT.
Comparing recipient characteristics, recipients of DCD livers
were more likely to have HCC as the primary indication for the
transplantation and to have blood group O (Table 1B). However,
they were less likely to be inpatients immediately before the
transplantation and to have had previous abdominal surgery.
Over time, donor and recipient characteristics remained largely
unchanged.
Time period-specific changes in
post-transplantation outcomes
Across the two time periods of transplantation, a significant im-
provement in patient mortality was identified in recipients of a
DCD liver, but not in those who received a DBD liver. Three-year
patient mortality in DCD liver recipients decreased from 19.6 per
cent (95 per cent c.i. 15.9 to 24.1) in time period 1 to 10.4 per cent
(95 per cent c.i. 7.9 to 13.8) in time period 2 (P< 0.001; Fig. 2),
whereas DBD recipient mortality decreased only from 12.8 per
cent (95 per cent c.i. 10.3 to 13.6 ) to 11.3 per cent (95 per cent c.i.
9.7 to 13.1) (P¼ 0.702). In recipients of a DCD liver, a non-
significant improvement in overall graft failure (defined as failure
of graft or death) was observed from 24.6 per cent (95 per cent c.i.
20.5 to 29.4) in time period 1 to 21.2 per cent (95 per cent c.i. 17.9
to 25.1 ) (P¼ 0.171; Fig. 3) in time period 2. No time period-related
improvements in graft failure were observed in recipients of a
DBD liver.
Following case mix adjustment, the pattern of results
remained the same. Comparing time period 2 to time period 1,
post-transplant mortality decreased by 57 per cent in those who
received a DCD liver, whereas in those who received a DBD liver,
no statistically significant improvements in mortality were ob-
served (Table 2). For graft failure at 3 years, no statistically signifi-
cant time period-specific improvements were identified for either
DCD or DBD liver recipients (Table 3).
The results presented above demonstrate that there was no
statistically significant difference in 3-year mortality in time pe-
riod 2 between recipients of DCD livers and those of DBD livers
(adjusted HR 0.78, 95 per cent c.i. 0.56 to 1.09; P¼ 0.142) (Table S1),
but 3-year graft loss was increased in recipients of DCD livers (ad-
justed HR 1.71, 95 per cent c.i. 1.33 to 2.18; P< 0.001).
Time-period specific changes in
retransplantation
Considering death as a competing event, we found an increase in
the 3-year retransplantation rate in recipients of a DCD liver
(from 7.3 per cent in time period 1 to 11.8 per cent in time period
2; P¼ 0.042), but no corresponding change in recipients of a DBD
liver (from 4.9 per cent in time period 1 to 4.5 per cent in time pe-
riod 2; P¼ 0.365). However, these changes were not statistically
significant with adjustment for donor and recipient characteris-
tics in both recipients of a DCD liver (adjusted subdistribution HR
1.47, 95 per cent c.i. 0.91 to 2.36; P¼ 0.127) and those of a DBD
liver (adjusted subdistribution HR 0.88, 95 per cent c.i. 0.63 to
1.23; P¼ 0.405). Further, there was no statistically significant evi-
dence that changes in the retransplantation rate over time dif-
fered between donation type (P interaction¼ 0.056). We also
found that only 2.0 per cent (7 of 348) of all patients who under-
went retransplantation received a DCD liver as their second do-
nor graft and all seven patients had received a DCD liver for their
first transplant.
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Time period-specific changes in postoperative
complications
A decrease in the frequency of postoperative renal failure oc-
curred in recipients of a DCD liver, but an increase of this fre-
quency was found in recipients of a DBD liver (Table 4). Another
remarkable change was an increase in portal thrombosis rate in
recipients of a DBD liver from time period 1 to time period 2.
Interestingly, no statistically significant change was identified in
the era-specific incidence of biliary tract strictures or leaks and
this was the same for both recipients of a DCD liver and those of
a DBD liver.
Time period-specific changes in causes of death
and graft failure
In recipients of a DCD liver, there was a reduction between time
period 1 and time period 2 in the proportion of patients dying
within 3 years from sepsis-related causes (from 8.5 per cent (31 of
363) to 3.1 per cent (25 of 813); P< 0.001) (Table S2), cardiac failure
(from 2.2 per cent (8 of 363) to 0.2 per cent (2 of 813); P< 0.001),
and tumour recurrence (from 1.9 per cent (7 of 363) to 0.4 per
cent (3 of 813); P¼ 0.008). In recipients of a DBD liver, there were
no such reductions in death from these causes and the only sig-
nificant improvements were in the proportion of patients dying
from recurrence of benign disease (from 0.5 per cent (8 of 1520) to
0.0 per cent (0 of 2229); P< 0.001) and those whose death was
recorded as unknown (from 0.9 per cent (14 of 1520) to 0.2 per
cent (5 of 2229); P¼ 0.003).
There was little time period-specific change in causes of graft
failure both for recipients of a DCD liver and for those of a DBD
liver, except for a decrease in the frequency of recurrent liver dis-
ease—including hepatitis C virus (HCV) and cholestatic liver dis-
eases (Table S3).
Sensitivity analyses
In a sensitivity analysis exploring time period-related improve-
ments in distinct epochs of follow-up time, statistically signifi-
cant time period-related improvements in mortality and graft
failure from 0 to 1 year were observed for DCD liver recipients
(HR 0.32, 95 per cent c.i. 0.21 to 0.51 and HR 0.69, 95 per cent c.i.
0.50 to 0.96, respectively) (Table S4), but not for DBD liver recipi-
ents (HR 0.91, 95 per cent c.i. 0.73 to 1.13 and HR 0.94, 95 per cent
c.i. 0.73 to 1.23, respectively). In the epoch of follow-up time from
1 to 3 years, no time period-related improvements were seen in
either cohort (Table S4).
In all multivariable models, adjustment for recipient charac-
teristics, and for both recipient and donor characteristics com-
bined, had only a small impact on the time trends observed in
post-transplant mortality or graft failure. This is a result of recipi-
ent and donor characteristics remaining largely stable over time.
Similarly, in the second sensitivity analysis, additional adjust-
ment for donor WIT in DCD liver recipients had very little impact
on the pattern of results (Table S5).
In the final sensitivity analysis, additional adjustment for
transplant centre volume also had little impact of time period on
patient mortality (adjusted HR 0.43, 95 per cent c.i. 0.30 to 0.61) or
graft failure (adjusted HR 0.95, 95 per cent c.i. 0.77 to 1.18), and
transplant centre volume was not found to be an independent
risk factor for either outcome (adjusted HR 1.08, 95 per cent c.i.
0.75 to 1.55, P¼ 0.664; adjusted HR 0.97, 95 per cent c.i. 0.75 to
1.24, P¼ 0.786). Global Wald tests found that time period-related
differences in post-transplant mortality or graft failure did not
differ according to whether patients were transplanted for HCC
or non-HCC indications, within either the DCD or DBD cohort (pa-
tient mortality: P¼ 0.622 and P¼ 0.401 for DCD and DBD cohorts,
respectively; graft failure: P¼ 0.096 and P¼ 0.592 for DCD and
DBD cohorts, respectively).
Discussion
In the last decade, the number of liver transplant recipients who
received a DCD liver has continually increased and DCD livers
have been increasingly more likely to have capsular damage or
an appearance documented as abnormal. However, mortality
has more than halved for those who received a DCD liver, while
remaining unchanged in recipients of a DBD liver. In particular,
there have been decreases in DCD recipients who died from sep-
tic and cardiac-related causes.
Analysis of the United Network for Organ Sharing (UNOS)
database, including 3199 DCD recipients from 2003 to 20149,
demonstrated era-related reductions in both patient mortal-
ity and graft failure, whereas a meta-analysis published in
2014, representing the results from 24 studies and 24 204
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Fig. 1 Time trends in utilization of DCD livers (1176 patients)
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Table 1 Donor and recipient characteristics according to period and stratified by donation type










Number DCD recipients 1176 363 813
DBD recipients 3749 1520 2229
Donor characteristics
Female DCD 474 (40.3%) 153 (42.2%) 321 (39.5%) 0.0% (0)
DBD 1813 (48.4%) 752 (49.5%) 1061 (47.6%) 0.0% (0)
Age (years), mean (s.d.) DCD 48.0 (16.3) 45.0 (15.8) 49.3 (16.4) 0.0% (0)
DBD 49.6 (16.0) 48.3 (15.6) 50.5 (16.2) 0.0% (0)
BMI (kg/m2), mean (s.d.) DCD 25.5 (4.6) 25.0 (4.7) 25.6 (4.9) 0.2% (2)
DBD 26.6 (5.0) 25.3 (3.9) 26.8 (5.1) 0.2% (8)
Trauma as cause of death DCD 126 (10.7%) 61 (16.8%) 65 (8.0%) 0.0% (0)
DBD 270 (7.2%) 131 (8.6%) 139 (6.2%) 0.0% (0)
Hepatic steatosis DCD 446 (38.4%) 128 (35.5%) 318 (39.8%) 1.3% (15)
DBD 1764 (47.9%) 728 (48.9%) 1036 (47.3%) 1.8% (69)
Presence of capsular damage DCD 236 (20.3%) 661 (8.3%) 170 (21.3%) 1.3% (15)
DBD 447 (12.2%) 206 (13.8%) 241 (11.0%) 2.1% (77)
Abnormal donor liver appearance DCD 296 (30.7%) 93 (35.1%) 203 (29.0%) 17.9% (211)
DBD 716 (22.5%) 310 (24.7%) 406 (21.1%) 15.2% (570)
Segmental graft type DCD 1 (0.1%) 1 (0.3%) 0 (0.0%) 0.0% (0)
DBD 402 (10.7%) 172 (11.3%) 230 (10.3%) 0.0% (0)
DBD 536.2 (160.7) 548.3 (133.6) 527.5 (163.8) 7.9% (296)
DLI, mean (s.d.) DCD 1.93 (0.40) 1.89 (0.38) 1.99 (0.40) 3.1% (36)
DBD 1.16 (0.23) 1.14 (0.23) 1.17 (0.23) 3.7% (139)
WIT (min)—agonal phase, mean (s.d.) DCD 15.3 (7.6) 15.9 (7.8) 15.0 (7.2) 26.2% (308)
DBD N/A N/A N/A N/A
WIT (min)—asystolic, mean (s.d) DCD 11.0 (40.9) 11.8 (4.0) 10.6 (48.7) 7.7% (91)
DBD N/A N/A N/A N/A
ABO match—identical DCD 1 147 (97.5%) 347 (95.6%) 800 (98.4%) 0.0% (0)
DBD 283 1 504 (98.9%) 2 199 (98.7%) 0.0% (0)
B. Recipient characteristics
Female DCD 383 (32.7%) 113 (31.3%) 270 (33.3%) 0.4% (5)
DBD 1218 (32.7%) 518 (34.2%) 700 (31.7%) 0.7% (25)
Age (years), mean (s.d.) DCD 54.6 (9.8) 54.2 (9.5) 54.9 (9.6) 0.0% (0)
DBD 52.4 (11.8) 52.1 (11.4) 52.6 (12.1) 0.0% (0)
Non-white ethnicity DCD 153 (13.0%) 59 (16.3%) 94 (11.6%) 0.1% (1)
DBD 462 (12.3%) 208 (13.7%) 254 (11.4%) 0.03% (1)
Hepatocellular carcinoma indication for transplant DCD 375 (31.9%) 119 (32.8%) 256 (31.5%) 0.0% (0)
DBD 830 (22.1%) 359 (23.6%) 471 (21.1%) 0.0% (0)
BMI (kg/m2), mean (s.d.) DCD 27.2 (4.9) 26.8 (4.6) 27.4 (5.0) 0.1% (1)
DBD 27.3 (5.3) 26.9 (5.0) 27.6 (5.4) 0.1% (4)
UKELD, mean (s.d.) DCD 53.7 (5.1) 54.1 (5.5) 53.5 (4.9) 1.0% (12)
DBD 55.0 (5.8) 54.9 (5.9) 55.1 (5.7) 0.7% (28)
Waiting list time (days), mean (s.d.) DCD 133.1 (147.0) 113.6 (114.2) 141.9 (158.9) 0.4% (5)
DBD 157.7 (199.4) 144.0 (162.6) 161.5 (204.6) 0.6% (24)
Blood group O DCD 545 (46.5%) 173 (47.9%) 372 (45.9%) 0.4% (5)
DBD 1469 (39.4%) 595 (39.3%) 874 (39.5%) 0.6% (24)
Functional status: self-care* DCD 491 (42.4%) 139 (39.3%) 352 (43.7%) 1.4% (17)
DBD 1699 (45.9%) 693 (46.1%) 1006 (45.8%) 1.9% (46)
Ascites DCD 608 (52.0%) 180 (49.6%) 428 (53.0%) 0.5% (6)
DBD 2018 (54.0%) 789 (52.0%) 1229 (55.3%) 0.3% (10)
Previous variceal bleed DCD 306 (26.4%) 112 (30.9%) 194 (24.3%) 1.3% (15)
DBD 892 (24.1%) 378 (25.0%) 514 (23.4%) 1.1% (41)
Encephalopathy DCD 337 (29.1%) 99 (27.4%) 238 (29.8%) 1.4% (16)
DBD 1629 (27.0%) 435 (28.9%) 706 (32.6%) 0.4% (16)
Presence of HCV antibodies DCD 254 (22.7%) 87 (25.4%) 167 (21.6%) 5.0% (59)
DBD 674 (19.1%) 317 (22.9%) 357 (16.7%) 5.9% (223)
Inpatient prior to transplant DCD 113 (9.6%) 47 (13.0%) 66 (8.1%) 0.2% (2)
DBD 554 (14.8%) 240 (15.8%) 314 (14.1%) 0.1% (4)
Renal support prior to transplant DCD 54 (4.6%) 20 (5.5%) 34 (4.2%) 0.2% (3)
DBD 180 (4.8%) 54 (3.6%) 126 (5.7%) 0.2% (12)
Previous abdominal surgery DCD 85 (7.3%) 35 (9.7%) 50 (6.2%) 0.3% (4)
DBD 497 (13.3%) 214 (14.1%) 283 (12.7%) 0.3% (11)
*Third-level of 5-point scale assessing a patient’s pretransplantation functional status. DCD, donors of liver donated after circulatory death (DCD); DBD, donors of
liver donated after brainstem death. DLI, Donor Liver Index. Donor factors, including DCD, segmental graft, height, age, smoking status, and bilirubin. WIT, warm
ischaemic time. UKELD, United Kingdom Model for End-stage Liver Disease; HCV, hepatitis C virus.
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Fig. 3 Three-year graft survival across different periods of transplantation (2008–2011 and 2012–2016) in recipients receiving a DCD or DBD liver
(4925 patients)
Table 2 Effect of time period on 3-year post-transplant mortality in patients receiving a DCD or DBD liver
Period of transplantation




P-value for effect of
time period
Hazard ratio (95% c.i.)
DCD patients
Unadjusted 1 0.45 (0.32–0.64) < 0.001
Adjusted for recipient
characteristics only*
1 0.44 (0.31–0.62) < 0.001
Adjusted for recipient and
donor characteristics†
1 0.43 (0.30–0.62) < 0.001
DBD patients
Unadjusted 1 0.94 (0.76–1.16) 0.572
Adjusted for recipient
characteristics only*
1 0.96 (0.78–1.18) 0.706
Adjusted for recipient and
donor characteristics†
1 0.96 (0.78–1.19) 0.732
*Adjusted for recipient characteristics: sex, age, ethnicity, BMI (kg/m2), functional status, ascites, varices, encephalopathy, hepatitis C virus (HCV) status, United
Kingdom Model for End-stage Liver Disease (UKELD), pretransplant inpatient status, pretransplant renal support, previous abdominal surgery, and transplant unit.
†Adjusted for recipient characteristics listed above and for donor characteristics: sex, age, BMI (kg/m2), cause of death, donor type (donation after circulatory death
or donation after brainstem death), steatosis, capsular damage, organ appearance, graft type, and cold ischaemic time.
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DCD recipients, compared to 16 per cent of DBD recipi-
ents9,34. However, our results are in line with a European
study comparing outcomes in 124 recipients of a DCD liver
and 1264 recipients of a DBD liver, published in 2016, that
concluded that after DCD liver transplantation, there is in-
creased graft failure, but no difference in patient survival35.
Increases in the overall donation rates in the UK were almost
entirely due to the expansion of DCD programmes36. Compared
with many other countries, the rate of DBD donation was ‘strik-
ingly’ low for many years in the UK and attributable to a consis-
tency in the clinical decision-making process that limited or
withdrew treatments to patients with non-survivable brain inju-
ries before brainstem death has evolved or can be diagnosed36. In
fact, in the UK, it was estimated that one-quarter of all patients
who fulfilled the preconditions of brainstem death testing did not
have tests for brainstem death carried out36.
By contrast, the proliferation of DCD transplantation in the UK
and Ireland is likely to be a reflection of the number of deaths in
intensive care that follow a decision to withdraw life-sustaining
treatments that are considered to be of no benefit to the critically
ill patient37. Therefore, increases in DCD liver donation can, at
least at an institutional level, be attributed to the resolution of le-
gal and ethical obstacles to this form of donation37. In this con-
text, DCD donation at a professional level may also now be
viewed as part of the care that a person might wish to receive at
the end of their life37.
Table 3 Effect of time period on 3-year graft failure in patients receiving a DCD or DBD liver
Period of transplantation
Status of case mix adjustment Time period 1: 2008–2011 Time period 2: 2012–2016 P-value for effect of time period
Hazard ratio (95% c.i.)
DCD patients
Unadjusted 1 0.83 (0.63–1.09) 0.189
Adjusted for recipient
characteristics only*
1 0.82 (0.62–1.08) 0.153
Adjusted for recipient and
donor characteristics†
1 0.80 (0.61–1.05) 0.116
DBD patients
Unadjusted 1 0.93 (0.78–1.11) 0.572
Adjusted for recipient
characteristics only*
1 0.95 (0.79–1.14) 0.562
Adjusted for recipient and
donor characteristics†
1 0.95 (0.79–1.14) 0.607
*Adjusted for recipient characteristics: sex, age, ethnicity, BMI (kg/m2), functional status, ascites, varices, encephalopathy, hepatitis C virus (HCV) status, United
Kingdom Model for End-stage Liver Disease (UKELD), pretransplant inpatient status, pretransplant renal support, previous abdominal surgery, and transplant unit.
†Adjusted for recipient characteristics listed above and for donor characteristics: sex, age, BMI (kg/m2), cause of death, donor type (donation after circulatory death
or donation after brainstem death), steatosis, capsular damage, organ appearance, graft type, and cold ischemic time.
Table 4 Postoperative complications reported at 3 months and stratified by donation type
Period of transplantation
Overall: 2008–2016 Time period 1: 2008–
2011
Time period 2: 2012–
2016
P-value for effect of
time period
Number DCD recipients 1176 363 813
DBD recipients 3749 1520 2229
Biliary complications
Biliary tract leak DCD 68 (5.8%) 17 (4.7%) 51 (6.3%) 0.318
DBD 199 (5.3%) 75 (4.9%) 124 (5.6%) 0.421
Biliary tract stricture DCD 74 (6.3%) 18 (5.0%) 56 (6.9%) 0.242
DBD 163 (4.4%) 57 (3.8%) 106 (4.8%) 0.160
Vascular complications
Hepatic artery thrombosis DCD 46 (3.9%) 18 (5.0%) 28 (3.4%) 0.240
DBD 106 (2.8%) 50 (3.3%) 56 (2.5%) 0.176
Portal vein thrombosis DCD 38 (3.2%) 12 (3.3%) 26 (3.2%) 0.932
DBD 116 (3.1%) 22 (1.5%) 94 (4.2%) < 0.001
IVC occlusion DCD 14 (1.2%) 4 (1.1%) 10 (1.2%) 0.857
DBD 37 (1.0%) 19 (1.3%) 18 (0.8%) 0.183
Haemorrhage DCD 84 (7.1%) 26 (7.2%) 58 (7.1%) 0.991
DBD 243 (6.5%) 115 (7.6%) 128 (5.7%) 0.046
Infection
Sepsis* DCD 436 (37.1%) 122 (33.6%) 314 (38.6%) 0.265
DBD 1381 (36.8%) 526 (34.6%) 855 (37.4%) 0.112
Renal failure
Renal failure DCD 224 (19.1%) 76 (20.9%) 312 (14.0%) < 0.001
DBD 487 (13.0%) 175 (11.5%) 148 (18.2%) < 0.001
*Includes sepsis from bacterial, fungal, and viral infections. Values are numbers with percentages in parentheses. DCD, donation following circulatory death; DBD,
donation following brainstem death; IVC, inferior vena cava.
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We observed substantial improvements in patient mortality
over time, but only for DCD recipients and only in the first year a
transplantation. Potential explanations for these improvements
in early post-transplant mortality are reductions in both the pro-
portion of DCD patients who died as a result of sepsis, cardiac
failure, and tumour recurrence and the proportion of patients
whose postoperative rehabilitation was complicated by renal fail-
ure. This demonstrates that the selection of recipients for DCD
transplantation is at least as important as the selection of donors
as an explanation for the time period-specific improvements.
The identified improvements in graft survival were again lim-
ited to DCD recipients and only found to be significant in the first
year after transplantation. These improvements are likely to be
attributable to a multitude of factors that may include improve-
ment in surgical and endoscopic techniques (the latter for post-
operative treatment of biliary complications), reductions in
overall ischaemic times, and a more optimal allocation of DCD
livers to patients with primary liver diseases—particularly HCC
patients—that do better with this type of donation5–9.
Failure to demonstrate improved longer-term graft survival in
either DCD or DBD recipients is more difficult to explain. It is pos-
sible that an overall deterioration in the quality of donors and in-
ability for retrieval of DCD donors to fully mitigate against the
deleterious effects of the inevitable WIT—including biliary com-
plications—could have prevented improvements in longer-term
graft loss5–9,11.
A strength of our study is that we described the results of all
transplantations carried out in the UK and Ireland and that we
had near-complete follow-up. Our results therefore provide a
steady benchmark of what post-transplant outcomes can be
achieved with both donation types. In addition, several studies
have demonstrated the validity of the data available in the
Standard National Liver Transplant Registry4,27.
A first limitation of our study is that the adjustment for donor
and recipient characteristics may not have fully captured the
time period-related differences in recipient and donor character-
istics. However, we adjusted for a wide range of characteristics
and therefore, it is unlikely that changes over time in recipient
and donor characteristics explain the large reduction in post-
transplant outcomes in recipients of DCD livers. Second, the fre-
quency of HAT and biliary complications in the first 3 months fol-
lowing transplantation may be an underestimate of their true
frequency, as it is known that they can be difficult to detect38.
However, we note that the frequency of complications that we
found is consistent with other studies39. Third, we did not have
complete follow-up for some patients transplanted in the second
time period of transplantation. In our adjusted analyses, this
could have led to an overestimation of the mortality rate in time
period 2 and an underestimation of the improvement over time
in post-transplantation mortality.
The study has implication for countries with high waiting
list mortalities and low rates of DCD utilization40, especially as
mortality following liver transplantation now appears to be
comparable for patients receiving DCD and DBD livers41.
However, we must also acknowledge that, although use of
DCD livers has dramatically increased the donor pool, approx-
imately 10 per cent of first-time elective DCD liver recipients
still require retransplantation and the graft used for retrans-
plantation typically come from the limited pool of DBD donors.
This is likely to be acceptable to both patients and service pro-
viders, as it improves the prognosis of the primary liver dis-
ease that led to the need for transplantation and helps to
reduce waiting list mortalities.
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